FY2025 Earnings Forecast for IONS Issued By Leerink Partnrs

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Investment analysts at Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a report released on Monday, September 15th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($2.78) per share for the year, up from their previous forecast of ($2.79). The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ Q4 2025 earnings at ($1.42) EPS.

Other equities analysts also recently issued reports about the company. Wells Fargo & Company increased their target price on Ionis Pharmaceuticals from $77.00 to $82.00 and gave the stock an “overweight” rating in a research note on Friday, August 22nd. Citigroup increased their target price on Ionis Pharmaceuticals from $69.00 to $84.00 and gave the stock a “buy” rating in a research note on Wednesday, September 3rd. Piper Sandler increased their target price on Ionis Pharmaceuticals from $62.00 to $65.00 and gave the stock an “overweight” rating in a research note on Friday, August 22nd. The Goldman Sachs Group increased their target price on Ionis Pharmaceuticals from $40.00 to $45.00 and gave the stock a “sell” rating in a research note on Wednesday, September 3rd. Finally, BMO Capital Markets raised Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $40.00 to $70.00 in a research note on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $67.88.

Ionis Pharmaceuticals Stock Down 0.2%

IONS opened at $61.17 on Wednesday. The business has a 50 day moving average price of $46.95 and a two-hundred day moving average price of $38.02. The company has a quick ratio of 2.86, a current ratio of 2.87 and a debt-to-equity ratio of 0.99. The company has a market cap of $9.75 billion, a PE ratio of -33.24 and a beta of 0.28. Ionis Pharmaceuticals has a 52 week low of $23.95 and a 52 week high of $64.71.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.19 by $0.51. The firm had revenue of $452.00 million during the quarter, compared to the consensus estimate of $270.90 million. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%.The firm’s revenue was up 100.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.45) EPS. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its holdings in Ionis Pharmaceuticals by 123.2% in the second quarter. Osaic Holdings Inc. now owns 5,296 shares of the company’s stock valued at $209,000 after acquiring an additional 2,923 shares during the last quarter. Orion Porfolio Solutions LLC acquired a new position in shares of Ionis Pharmaceuticals during the second quarter worth about $221,000. Marex Group plc acquired a new position in shares of Ionis Pharmaceuticals in the second quarter worth about $3,294,000. CANADA LIFE ASSURANCE Co lifted its stake in shares of Ionis Pharmaceuticals by 6.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 46,501 shares of the company’s stock worth $1,841,000 after acquiring an additional 2,648 shares in the last quarter. Finally, Corient Private Wealth LLC lifted its stake in shares of Ionis Pharmaceuticals by 0.3% in the second quarter. Corient Private Wealth LLC now owns 237,931 shares of the company’s stock worth $9,401,000 after acquiring an additional 798 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insider Activity at Ionis Pharmaceuticals

In related news, EVP C Frank Bennett sold 33,909 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $60.62, for a total value of $2,055,563.58. Following the transaction, the executive vice president owned 101,570 shares in the company, valued at approximately $6,157,173.40. This trade represents a 25.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Patrick R. O’neil sold 76,850 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $60.97, for a total value of $4,685,544.50. Following the completion of the transaction, the executive vice president owned 5,655 shares in the company, valued at $344,785.35. The trade was a 93.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 492,841 shares of company stock valued at $28,595,925 in the last ninety days. 2.60% of the stock is owned by insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.